StemCell Therapy

Puma Biotechnology Inc (NYSE:PBYI) has earned an average recommendation of Hold from the eight analysts that are covering the company. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $70.50.

Several brokerages have recently weighed in on PBYI. Royal Bank of Canada reissued a sector perform rating and issued a $17.00 price objective (down from $48.00) on shares of Puma Biotechnology in a research report on Thursday, March 2nd. Stifel Nicolaus reissued a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, November 30th. Citigroup Inc reissued a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Saturday, March 4th. Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research report on Tuesday, January 10th. Finally, Credit Suisse Group AG reissued an outperform rating on shares of Puma Biotechnology in a research report on Wednesday, January 18th.

Puma Biotechnology (NYSE:PBYI) opened at 44.15 on Tuesday. Puma Biotechnology has a 52-week low of $19.74 and a 52-week high of $73.27. The firms market capitalization is $1.63 billion. The firm has a 50-day moving average of $36.87 and a 200-day moving average of $43.70.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($2.04) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($1.92) by $0.12. On average, equities research analysts forecast that Puma Biotechnology will post ($8.32) EPS for the current fiscal year.

In related news, SVP Richard Paul Bryce sold 2,293 shares of the firms stock in a transaction dated Friday, January 20th. The shares were sold at an average price of $33.24, for a total transaction of $76,219.32. Following the transaction, the senior vice president now directly owns 29,237 shares of the companys stock, valued at $971,837.88. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert Charnas sold 3,008 shares of the firms stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $31.83, for a total transaction of $95,744.64. Following the transaction, the insider now directly owns 28,461 shares in the company, valued at $905,913.63. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,503 shares of company stock worth $511,078. 22.70% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. raised its position in Puma Biotechnology by 2.4% in the third quarter. UBS Asset Management Americas Inc. now owns 12,891 shares of the biopharmaceutical companys stock worth $864,000 after buying an additional 300 shares in the last quarter. California State Teachers Retirement System raised its position in Puma Biotechnology by 1.0% in the third quarter. California State Teachers Retirement System now owns 52,275 shares of the biopharmaceutical companys stock worth $3,505,000 after buying an additional 500 shares in the last quarter. BlackRock Investment Management LLC raised its position in Puma Biotechnology by 1.2% in the third quarter. BlackRock Investment Management LLC now owns 92,595 shares of the biopharmaceutical companys stock worth $6,208,000 after buying an additional 1,091 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical companys stock worth $163,000 after buying an additional 1,740 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in Puma Biotechnology by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,142 shares of the biopharmaceutical companys stock worth $618,000 after buying an additional 2,247 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Originally posted here:
The Brokerages Set Puma Biotechnology Inc (PBYI) PT at $70.50 - Petro Global News 24

This entry was posted on March 21, 2017 at 1:46 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |